Oncolytic viral therapy for pancreatic cancer

Rahal, A.; Musher, Benjamin

doi:10.1002/jso.24626

Cited by 39 publications

(31 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oncolytic viral therapy is a strategy that can induce tumor responses through direct tumor cell lysis by infecting tumor cells, replicating, and eventually lysing the cell. However, cell lysis also releases damage associated molecular pattern molecules (DAMPs) which can trigger innate and adaptive immune responses (76). Of these, adenovirus-based oncolytic viruses have been the most extensively evaluated.…”

Section: Oncolytic Viral Therapymentioning

confidence: 99%

“…Interestingly however, there was upregulation of PD-L1 in reolysin treated patients, again suggesting the potential immunomodulatory impact of oncolytic viral therapy in PAC (78). While these strategies seem to be limited by anti-tumor potency and immune neutralization, follow-up clinical studies utilizing reolysin in combination with anti-PD1 therapy (pembrolizumab) are ongoing(NCT02620423) (76).…”

Section: Oncolytic Viral Therapymentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapy in pancreatic adenocarcinoma—overcoming barriers to response

Rosenberg¹,

Mahalingam²

2018

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

Pancreatic adenocarcinoma (PAC) remains one of the leading causes of cancer-related death. Despite multiple advances in targeted and immune therapies, the 5-year survival in advanced PAC remains poor. In this review, we discuss some of the unique aspects of the tumor microenvironment (TME) in PAC that may contribute to its resistance to immune therapies, as well as opportunities to potentially overcome some of these inherent barriers. Furthermore, we discuss strategies to enable immune therapies in PAC such as cytotoxic chemotherapy and radiation therapy, cancer vaccines, cytokine based therapy, oncolytic viruses, and adoptive T-cell therapy. Finally, we address a variety of targeted therapies as a strategy to further amplify immune responses in PAC.

show abstract

Section: Oncolytic Viral Therapymentioning

confidence: 99%

Section: Oncolytic Viral Therapymentioning

confidence: 99%

Immunotherapy in pancreatic adenocarcinoma—overcoming barriers to response

Rosenberg¹,

Mahalingam²

2018

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

show abstract

“…On the other hand, the infection of tumor cells express pathogen‐associated molecular pattern molecules (PAMPs) and damage‐associated molecular pattern molecules (DAMPs), which induces the innate immune response through activation of toll‐like receptors. In turn, the activation of the innate immune system facilitates presentation of viral antigens and tumor‐associated antigens (TAAs) to prime the adaptive immune response . Of note, several common oncolytic viruses (eg, adenovirus, herpes simplex virus [HSV], vesicular stomatitis virus [VSV], vaccinia virus, and reovirus; Figure 1) have been proven to promote antitumor immunity .…”

Section: Introductionmentioning

confidence: 99%

Oncolytic virotherapy in hepato‐bilio‐pancreatic cancer: The key to breaking the log jam?

Shen

Zhao

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

Traditional therapies have limited efficacy in hepatocellular carcinoma, pancreatic cancer, and biliary tract cancer, especially for advanced and refractory cancers.Through a deeper understanding of antitumor immunity and the tumor microenvironment, novel immunotherapies are becoming available for cancer treatment. Oncolytic virus (OV) therapy is an emerging type of immunotherapy that has demonstrated effective antitumor efficacy in many preclinical studies and clinical studies. Thus, it may represent a potential feasible treatment for hard to treat gastrointestinal (GI) tumors. Here, we summarize the research progress of OV therapy for the treatment of hepato-bilio-pancreatic cancers. In general, most OV therapies exhibits potent, specific oncolysis both in cell lines in vitro and the animal models in vivo. Currently, several clinical trials have suggested that OV therapy may also be effective in patients with refractory hepato-bilio-pancreatic cancer. Multiple strategies such as introducing immunostimulatory genes, modifying virus capsid and combining various other therapeutic modalities have been shown enhanced specific oncolysis and synergistic anti-cancer immune stimulation. Combining OV with other antitumor therapies may become a more effective strategy than using virus alone. Nevertheless, more studies are needed to better understand the mechanisms underlying the therapeutic effects of OV, and to design appropriate dosing and combination strategies. K E Y W O R D Sbiliary tract cancer, hepatocellular carcinoma, immunotherapy, oncolytic virus, pancreatic cancer 2944 |

show abstract

“…It may require combining agents that dissolve the cancer‐protecting stroma, with small molecules, and antibodies targeting cancer growth and metastasis pathways . It may require adding molecules, viruses, and cells active in cancer killing through stimulation of the immune system, or vaccines to prevent recurrence …”

mentioning

confidence: 99%

“…It may require combining agents that dissolve the cancer-protecting stroma, 8 with small molecules, [9][10][11] and antibodies targeting cancer growth and metastasis pathways. 12,13 It may require adding molecules, 14 viruses, 15 and cells 16,17…”

mentioning

confidence: 99%